Sugi Predict

Sugi Predict / Compounds / SCHEMBL178373

SCHEMBL178373

SCHEMBL178373

Cc1ccc(NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP17A1 P05093 2/20 0.54
▸ TDP1 Q9NUW8 1/20 0.53
▸ POLB P06746 1/20 0.52
▸ CA12 O43570 1/20 0.51
▸ CA1 P00915 1/20 0.51
▸ CA9 Q16790 1/20 0.51
▸ PSMB8 P28062 1/20 0.51
▸ NAMPT P43490 1/20 0.51
▸ RAB9A P51151 4/20 0.50
▸ NPC1 O15118 3/20 0.50
▸ TP53 P04637 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ KIF11 P52732 1/20 0.47
▸ TGM2 P21980 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13055402 0.92 CYP17A1 (0.59) CYP17A1CA12CA1CA9PSMB8
SCHEMBL23966382 0.92 HPGD (0.53) CYP17A1TDP1CA12CA1CA9
SCHEMBL14379115 0.90 CYP17A1 (0.68) CYP17A1POLBCA12CA1CA9
SCHEMBL20865536 0.86 CYP17A1 (0.68) CYP17A1CA12CA1CA9PSMB8
SCHEMBL23619661 0.86 SMN1; SMN2 (0.62) CYP17A1POLBCA12CA1CA9
SCHEMBL23899107 0.86 KLK7 (0.54) CYP17A1POLBCA12CA1CA9
SCHEMBL23899106 0.85 SMN1; SMN2 (0.56) CYP17A1NAMPTRAB9ANPC1TP53
SCHEMBL17297272 0.85 ALDH1A1 (0.69) POLBCA12CA1CA9SMN1; SMN2
SCHEMBL977487 0.85 CYP17A1 (0.54) CYP17A1CA12CA1CA9PSMB8
SCHEMBL437131 0.85 CYP17A1 (0.54) CYP17A1TDP1POLBCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6630512-B2 Antiinflammatory agents; autoimmune disease BIOGEN, INC. 2003-10-07 — — US claimed
US-6624152-B2 Inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention relates to pharmaceutical formulations comprising these compounds and methods of using them for inflammatory and autoimmune diseases BIOGEN, INC. 2003-09-23 — — US claimed
US-20030083267-A1 Cell adhesion inhibitors BIOGEN, INC., A MASSACHUSETTS CORPORATION 2003-05-01 — — US claimed
US-20030018016-A1 Cell adhesion inhibitors BIOGEN IDEC MA, INC. 2003-01-23 — — US claimed
EP-0805796-B1 CELL ADHESION INHIBITORS BIOGEN INC (US) 2002-12-11 — — EP claimed
US-6376538-B1 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES BIOGEN, INC. 2002-04-23 — — US claimed
US-6306840-B1 ANTISTICKING AGENTS OF OLIGOPEPTIDES BIOGEN, INC. 2001-10-23 — — US claimed
EP-0805796-A1 CELL ADHESION INHIBITORS BIOGEN, INC. (US) 1997-11-12 — — EP claimed
WO-1996022966-A1 CELL ADHESION INHIBITORS BIOGEN, INC. (US) 1996-08-01 — — WO claimed
EP-4608816-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF Monte Rosa Therapeutics AG (CH) 2025-09-03 — — EP disclosed
US-20250263395-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2025-08-21 — — US disclosed
CN-119751307-A Preparation method of ilast and intermediate thereof 苏州华先医药科技有限公司 2025-04-04 — — CN disclosed
WO-2024092039-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2024-05-02 — — WO disclosed
US-20240068009-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES PROMEGA CORPORATION 2024-02-29 — — US disclosed
US-6100398-A Transition metal-catalyzed process for preparing N-aryl amine compounds YALE UNIVERSITY (US) 2000-08-08 — — US disclosed
EP-0805796-A1 CELL ADHESION INHIBITORS BIOGEN, INC. (US) 1997-11-12 — — EP disclosed
WO-1996022966-A1 CELL ADHESION INHIBITORS BIOGEN, INC. (US) 1996-08-01 — — WO disclosed
EP-0065864-B1 ANTI-HYPERTENSIVE 1-SUBSTITUTED SPIRO (PIPERIDINE-OXOBENZOXAZINES) SYNTEX (U.S.A.) INC. (US) 1985-08-28 — — EP disclosed
EP-0065864-A1 Anti-hypertensive 1-substituted spiro (piperidine-oxobenzoxazines) SYNTEX (U.S.A.) INC. (US) 1982-12-01 — — EP disclosed
US-4349549-A Anti-hypertensive 1-substituted spiro(piperidine-oxobenzoxazine)s SYNTEX (U.S.A.) INC. (US) 1982-09-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083267-A1 Cell adhesion inhibitors ICAM1, VCAM1, EPCAM CYP17A1 4493/4885TDP1 3364/4885POLB 4750/4885
US-20240068009-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES PGLS, AADAC, GLB1 CYP17A1 3730/4885TDP1 3422/4885POLB 3736/4885
US-20250263395-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF CDK2, SKP2, CDK1 CYP17A1 3289/4885TDP1 2330/4885POLB 1173/4885
US-20030018016-A1 Cell adhesion inhibitors ICAM1, VCAM1, EPCAM CYP17A1 4493/4885TDP1 3364/4885POLB 4750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.